Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gene ENSG00000288255 is annotated as a **pseudogene** of caspase 1, apoptosis-related cysteine peptidase, also referenced as interleukin 1, beta, convertase pseudogene[3]. Pseudogenes are gene sequences that resemble known genes but typically **lack the ability to code for a functional protein** due to mutations, truncations, or other genetic alterations[1]. They may arise from gene duplication or retrotransposition events and usually do not have biological functions or disease associations attributed to them directly. As a result, this pseudogene **is not a therapeutic target** and does *not* participate in classical biological processes or pathways attributed to the functional CASP1 gene or its protein product. The canonical, protein-coding CASP1 gene (not the pseudogene) is a cysteine protease central to **apoptosis and inflammatory signaling**, particularly through maturation of pro-interleukin-1β and execution of pyroptosis[2][4]. Functional caspase 1 enzymes are bona fide therapeutic targets in some contexts, but this **does not apply to the pseudogene** represented by ENSG00000288255. The confusion may arise because the symbol and full name resemble that of functional caspase 1, which is a well-characterized protease involved in inflammation and cell death. However, **ENSG00000288255 itself is a pseudogene and not a functional or druggable target**[3]. Proper care should be taken not to conflate this pseudogene with the protein-coding and therapeutically relevant CASP1 gene (ENSG00000137752)[5]. If you are seeking data relevant to the druggability and biology of **caspase 1**, refer specifically to the protein-coding gene (CASP1, ENSG00000137752), not this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Caspase 1, apoptosis-related cysteine peptidase pseudogene.